

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Pratt, et al.

Serial No.: 10/699,513

Filed: October 31, 2003

Title: ANTI-INFECTIVE AGENTS

Case No.: 6998US02



Group Art No.: (not yet assigned)

Examiner: (not yet assigned)

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the:

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450 on:

Date of Deposit: January 28, 2004

Tanya Parent 1/28/04
Tanya Parent Date

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL LETTER

Dear Sir:

Enclosed herewith for the patent application identified above entitled ANTI-INFECTIVE AGENTS are the following:

1. Information Disclosure Statement;
2. Form PTO 1449, in duplicate;
3. Reference as cited on PTO 1449 (15 reference); and
4. Return Receipt Postcard.

The Commissioner is hereby authorized to charge any additional Filing Fees required under 37 CFR §1.16, as well as any patent application processing fees under 37 CFR §1.17 associated with this communication for which full payment had not been tendered, to Deposit Account No. 01-0025.

ABBOTT LABORATORIES
Customer Number 23492
Telephone: (847) 935-7835
Facsimile: (847) 938-2623

Respectfully submitted,
Pratt, et al.

Kalim S. Fuzail
Registration No. 45,805
Attorney for Applicants

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Pratt, et al.

Serial No.: 10/699,513

Filed: October 31, 2003

Title: ANTI-INFECTIVE AGENTS

Case No.: 6998US02



Group Art No.: (not yet assigned)

Examiner: (not yet assigned)

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the:

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450 on:

Date of Deposit: January 28, 2004

Tanya Parent 1/28/04
Tanya Parent Date

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Dear Sir:


Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), Applicants bring to the attention of the Examiner the documents listed on the attached PTO 1449. This Information Disclosure Statement is being filed, to the knowledge of the undersigned, before the mailing date of a first Office Action on the merits. Applicants respectfully petition and request that the Examiner consider the listed documents and evidence such consideration by making appropriate notations on the attached form. Copies of the listed documents are attached.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.


The Commissioner is authorized to charge our Deposit Account any additional fees (or credit any over payments) that may be required under 37 C.F.R. §§ 1.16 and 1.17 in association with this communication for which full payment has not been tendered.

ABBOTT LABORATORIES
Customer Number 23492
Telephone: (847) 935-7835
Facsimile: (847) 938-2623

Respectfully submitted,
Pratt, et al.


Kalim S. Fuzail
Registration No. 45,805
Attorney for Applicants

Form PTO - 1449 (Modified)



DATE: January 28, 2004 SHEET 1 of 1

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE
(Modified) PATENT AND TRADEMARK OFFICEINFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)

(37 CFR 1.98 (b))

ATTY. DOCKET NO.

6998.US.02

SERIAL NO.

10/699,513

APPLICANT(S)

Pratt, et al.

FILING DATE

October 31, 2003

GROUP

Not yet assigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	INVENTOR	CLASS	SUB CLASS	FILING DATE
	A1	3,133,918	05/19/64				
	A2	3,291,794	12/13/66				
	A3	3,499,082	03/03/70				
	A4	5,378,704	01/03/95	Weller			

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

		DOCUMENT NUMBER	PUBLIC-ATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUB CLASS	TRANS- LATION YES NO
	B1	386435		CH			X
	B2	0 618 209	23.12.98	EP			X
	B3	885950		GB			
	B4	01/85172	15.11.01	WO			
	B5	02/98424	12.12.02	WO			
	B6	03/37262	08.05.03	WO			
	B7	03/59356	24.07.03	WO			

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

C1	Dhanak et al., "Identification and Biological Characterization of Heterocyclic Inhibitors of the Hepatitis C Virus RNA-dependent RNA Polymerase," Journal of Biological Chemistry 277(41); 38322-38327 (2002)
C2	Dhanak et al., "Identification and Biological Characterization of Heterocyclic Inhibitors of the Hepatitis C Virus RNA-Dependent RNA Polymerase," 9 th International Meeting on HCV and Related Viruses, July 7-11, 2002; San Diego, CA; Abstract #0-3, pg. 21.
C3	McHutchison, The American Association for the Study of Liver Diseases, Hepatitis Single Topic Conference: Hepatitis C New Drug and Clinical Trials Development: Promises and Pitfalls. Abstract #5; February 27-March 1, 2003, Chicago, IL
C4	Ukrainets et al., "4-Hydroxy-2-Quinolones. 42*. Synthesis and biological Activity of 1-R-2-Oxo-3-(2H-1,2,4-Benzothiadiazine-1,1-Dioxid-3-Yl)-4-Hydroxyquinolines," Chemistry of Heterocyclic Compounds 36(3):346-350 (2000)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Form PTO 1449)